



GREETINGS

HI

WELCOME

HELLO

HOWDY

GLAD YOU'RE HERE



# THANK YOU'S!

- Doug Furmanek
- Vito Cancellaro
- Alain Litwin
- Richele Taylor
- Necole Stinson
- Rebecca Brannon
- Sara Goldsby
- South Carolina Academy of Family Physicians

---

# RULES OF ENGAGEMENT!

- Open discussion
- Please be willing to share
- No judgement
- I don't want to talk the entire time!



---


# LEARNING OBJECTIVES

- Understand the impact of the opioid epidemic in South Carolina, the “WHY”
- Explain opioid stewardship and how it can improve a health system
- Discuss strategies on who to change your health system’s culture through education
- Open discussion of future opportunities

What's the  
**WHY**




# US OPIOID DISPENSING RATE, 2020



<https://www.cdc.gov/drugoverdose/rxrate-maps/state2020.html>

# U.S. TRENDS IN OPIOID PRESCRIBING & HIGH DOSES




Source: IQVIA® Transactional Data Warehouse

## Data Table

	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017
<b>All opioids/Overall</b>	72.4	75.9	78.2	79.5	81.2	80.9	81.3	78.1	75.6	70.6	66.5	58.5
<b>High-dosage</b>	11.5	11.7	11.8	11.5	11.4	8.8	8.3	7.6	7.1	6.7	6.1	5



# SC AVERAGE DAILY MME OF PRESCRIPTIONS




[https://justplainkillers.com/wp-content/uploads/2021/10/PMP\\_Final\\_Report.pdf](https://justplainkillers.com/wp-content/uploads/2021/10/PMP_Final_Report.pdf)

PRIVILEGED AND CONFIDENTIAL


protected pursuant to S.C. Code Ann. §§44-7-390 et seq. and 40-71-10 et seq.

# SC OPIOIDS QUANTITY VS. FILLED OVER TIME

Average prescription quantity dispensed for CII prescriptions over time




Number of filled CII prescriptions prescribed by SC prescribers over time



[https://justplainkillers.com/wp-content/uploads/2022/05/2021-pmp-annual\\_final\\_version.pdf](https://justplainkillers.com/wp-content/uploads/2022/05/2021-pmp-annual_final_version.pdf)

# SC OVERDOSE DEATHS (2017-2021)



**78.5%**  
of  
overdose  
deaths  
involve  
Fentanyl

<https://scdhec.gov/sites/default/files/media/document/Drug%20Overdose%20Report%202021.pdf>

PRIVILEGED AND CONFIDENTIAL

protected pursuant to S.C. Code Ann. §§44-7-390 et seq. and 40-71-10 et seq.

# HEALTHCARE CULTURE



"The doctor will see you now —  
I can't promise that he'll talk  
to you, but he'll see you."




# WHOSE RESPONSIBILITY?



**“I specialize in referrals to  
specialists!”**

# CASE FOR CHANGE: FOR THE SYSTEM I WORK FOR



[https://scdhec.gov/sites/default/files/media/document/Drug%20overdose%20report\\_2020\\_V1.pdf](https://scdhec.gov/sites/default/files/media/document/Drug%20overdose%20report_2020_V1.pdf)

# OPIOID EPIDEMIC !!!

CENTRAL NEW YORK  
**STATE OF ADDICTION**

OBSERVER-DISPATCH  
uticaOD.com

EYEWITNESS NEWS  
**WUTR abc**


**STATE OF ADDICTION**

CHRONICLE  
**STATE OF ADDICTION**  
WEDNESDAY, MARCH 22 AT 8PM

FENTANYL  
TRANS-DERMAL  
75 mcg/hr

# Chronic Pain Experience

Understand access to covered treatment and services for people with chronic pain.



PRIVILEGED AND CONFIDENTIAL

protected pursuant to S.C. Code Ann. §§44-7-390 et seq. and 40-71-10 et seq.



# PAIN?

## Four Decades Later: Revision of the IASP Definition of Pain and Notes

The currently accepted definition of pain was originally adopted in 1979 by the International Association for the Study of Pain (IASP)

### 1979 Definition of Pain

An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage

### 2020 Revised Definition of Pain

An unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage

In 2018, IASP constituted a 14-member multi-national task force with expertise in clinical and basic science related to pain, which sought input from multiple stakeholders to determine:

"Does the progress in our knowledge of pain over the years warrant a re-evaluation of the definition?"



Expert consultants



IASP council



The public

### 2020 Revised Definition of Pain Notes



Pain is always a personal experience that is influenced to varying degrees by biological, psychological, and social factors



Pain and nociception are different phenomena. Pain cannot be inferred solely from activity in sensory neurons



Through their life experiences, individuals learn the concept of pain



A person's report of an experience as pain should be respected



Although pain usually serves an adaptive role, it may have adverse effects on function and social and psychological well-being




Verbal description is only one of several behaviors to express pain; inability to communicate does not negate the possibility that a human or a nonhuman animal experiences pain

The revised IASP definition of pain: concepts, challenges, and compromises Raja et al. (2020) | Pain  
DOI: 10.1097/j.pain.0000000000001939

PRIVILEGED AND CONFIDENTIAL

protected pursuant to S.C. Code Ann. §§44-7-390 et seq. and 40-71-10 et seq.

# SOCIETAL IMPACT



PRIVILEGED AND CONFIDENTIAL

protected pursuant to S.C. Code Ann. §§44-7-390 et seq. and 40-71-10 et seq.

# DANGEROUS TRENDS



# WHO'S RESPONSIBLE?





# OPIOID STEWARDSHIP



# WHERE WE STARTED...

## >>> GETTING STARTED



- Developed the “team”
- Mission
- Structure
- Administrative support
- Survey
- Educational endeavors
- Institutional changes

---

# OVERARCHING GOAL OF THE OPIOID STEWARDSHIP COMMITTEE

To develop holistic patient-centered strategies that mitigate pain, optimize recovery and promote well-being for the communities we serve

---

# CHARTER...

## Opioid Stewardship Committee Charter

### **Mission Statement**

To develop holistic patient-centered strategies that mitigate pain, optimize recovery and promote well-being for the communities we serve.

### **Purpose**

To provide advisement on proposed evidence-based best practices, assist with mitigating barriers, and set the tone and behaviors for system-level coordination.


The Committee serves as an oversight and decision-empowering team for all seven hospital campuses which evaluate, vet, and recommend strategies (including methods, approaches, and processes) and tools (including technologies) for successful opioid prescribing.

The Committee has the authority to research, collaborate, vet, and recommend best practices in an effort to contribute to the goals of improving quality of care, clinical outcomes, and enhancing the patient experience.

### **Membership**




# ORGANIZATIONAL STRUCTURE



Workgroup Streams – Charged with Rolling out Initiatives


# HOW DO WE IMPROVE OPIOID SAFETY ?




- **Redefine patient pain expectations**
- Engage patient and families about the harms of opioid therapy
- Increase prescriber awareness
- Implement a data-driven process for improving safe prescribing
- Work with rehabilitation programs and community outreach programs
- Change the health culture of safe and appropriate prescribing

# PRACTITIONER PULSE CHECK ON OPIOIDS


What is your specialty?




What is your job title?




There is a national opioid epidemic.




I feel pressured to prescribe opioids.



Most patients would be receptive to using non-opioids.




Patients have unrealistic expectations about pain control.




# OPIOID STEWARDSHIP

## PHILOSOPHY FOR PROCESS IMPROVEMENT




# DATA-DRIVEN APPROACH TO CHANGE



# Vaginal Deliveries:

Average Total Discharge MME by Provider (95% Confidence Interval)




Data Source: Oct '17 – Dec '18

Note: Graph excludes MDs with < 20 Vaginal Delivery encounters with an opioid prescription at discharge

# Ordering MD: Orthopedics

Average Total Discharge MME (95% Confidence Interval)




Data Source: Jan '17 – Jul '18

Note: Graph excludes surgeons with < 30 discharges with an opioid prescription

# Emergency Departments:

Average Discharge MME (95% Confidence Interval)




Data Source: Jul '17 – Jun '18

Note: Graph excludes MDs with < 50 ED discharges with an opioid prescription



# Opioid Average Total Discharge MME (Morphine Milligram Equivalent) by Year Hospital Encounters (includes hospitalizations, inpatient and outpatient surgery visits, ED and urgent care visits)



No. of RX Sep '18 to Aug '19	31,557	11,353	1,236	9,515	1,126
No. of Rx Sep '19 to Aug '20	32,409	12,460	1,536	9,415	1,254
No. of Rx Sep '20 to Aug '21	33,433	12,545	2,185	8,989	1,116
No. of Rx Sep '21 to Aug '22	39,008	14,326	2,782	10,741	1,310



STRATEGIES...




# STRATEGY #1: EDUCATION.. EDUCATION..



PRIVILEGED AND CONFIDENTIAL

protected pursuant to S.C. Code Ann. §§44-7-390 et seq. and 40-71-10 et seq.



- + Effective, patient-centered care
- + Optimize patient functional outcomes
- + Appropriate use of pain medication
- + Eliminate stigma
- + Reduced risk through risk-benefit assessment

**Figure 19: Education Is Critical to the Delivery of Effective, Patient-Centered Pain Care and Reducing the Risk Associated With Prescription Opioids**

---


# PATIENT EDUCATION

- Get an accurate medication history
  - Identify naive vs. tolerant pain patients
- Set realistic pain expectations for patients
  - Begins with education in anesthesia pre-assessment
  - Nurse liaisons communicating pain plan of care to patients
- **Focus on function, not pain score**
- Alternative therapies
  - Non-pharmacological therapies (ice, heat, positioning, quiet time)
  - Multimodal therapy
- **Explain risks of opioids including side effects**
- Use whiteboards as a communication tool




---

# CULTURE CHANGE – OLD PRACTICE



---


# CULTURE CHANGE – CURRENT PRACTICE






# TREATMENT OF ACUTE PAIN


- Chronic opioid use often starts with treatment of acute pain
- **1 of 8** opioid naïve patients who receive narcotics after a procedure becomes persistent users
- Patients traditionally use less than **15% of total opioid RX**




# THE WHY BEHIND THE REALITY




morphine




hydrocodone




hydromorphone



codeine



oxycodone




heroin


PRIVILEGED AND CONFIDENTIAL

protected pursuant to S.C. Code Ann. §§44-7-390 et seq. and 40-71-10 et seq.

# PROGRESSION TO ADDICTION



# SOURCE OF OPIOID MISUSE




SAMHSA. (2020). 2019 National Survey on Drug Use and Health

PRIVILEGED AND CONFIDENTIAL

protected pursuant to S.C. Code Ann. §§44-7-390 et seq. and 40-71-10 et seq.

# WHERE TO START?



**Figure 17: A Risk Assessment Is Critical to Providing the Best Possible Patient-Centered Outcome While Mitigating Unnecessary Opioid Exposure**

# MAGIC IN A BOTTLE !!



AND



VS



PRIVILEGED AND CONFIDENTIAL

protected pursuant to S.C. Code Ann. §§44-7-390 et seq. and 40-71-10 et seq.

# FEDERAL OVERSIGHT

- 2014: C-II designation for hydrocodone
- 2016: CDC Guidelines on Chronic Pain
- 2022: Revised CDC Guidelines



## GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN

### IMPROVING PRACTICE THROUGH RECOMMENDATIONS

CDC's *Guideline for Prescribing Opioids for Chronic Pain* is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.

PRIVILEGED AND CONFIDENTIAL

protected pursuant to S.C. Code Ann. §§44-7-390 et seq. and 40-71-10 et seq.

# CONSEQUENCES: 2016 CDC OPIOID GUIDELINES

- 2012: Opioid prescriptions peaked at **255 million**
- 2016: **214 million** opioid prescriptions were dispensed
- 2017: Opioid prescriptions **dropped by over 22 million**
  - Prescribers began to deprescribe opioids inappropriately
    - Many dependent patients experienced withdrawal
    - Sought illegal manners of attaining opioids or other drugs (heroin)
- 2019: FDA states the deprescribing of opioids can lead to patient harm from the rapid discontinuation of opioids
  - Providers & patients work together to slowly taper opioid therapy



---

# 2022 CDC GUIDELINE SUMMARY

- 2022 CDC Guidelines are intended to improve clinician and patient communication about benefits / risks of pain treatment
  - Improve the effectiveness and safety of pain treatment
  - Mitigate pain
  - Improve function and quality of life for patients with pain
  - Reduce risks associated with opioid pain therapy
- Evidence to guide optimal pain management remains limited
- Patient-clinician communication are key to treatment decisions
- Updated guideline can help inform those decisions


# HOW TO MANAGE?...LEGACY PTS

- August 2019:
  - Pain Management Associates closed in Greenville County
    - Leaving **25000** patients seeking care
  
- May 2021:
  - Lags Medical Center pain management clinics closed...
    - Leaving **20000** patients without care



Coffin P, et al. *N Engl J Med* 386:7, 2022, pp 611-613

# RISKS OF DISCONTINUATION



## Steps in Caring for Patients with Chronic Pain Who Have Received Long-Term Opioid Therapy from a Previous Clinician.

- 1. Review the case with the former clinician if possible.** Try to develop a treatment plan that slowly adjusts to your style of management while avoiding a radical divergence from the previous plan of care.
- 2. Consider providing a therapeutic bridge for the patient until a plan of care is determined, given the risks associated with stopping opioid therapy.** Abruptly tapering or stopping opioid therapy can be dangerous for multiple reasons. Opioids may be crucial for the patient's condition (e.g., sickle-cell disease), and the patient may be at risk for other harms when opioids are tapered or discontinued (see figure).
- 3. Develop a patient-centered care plan.** If a taper is needed, empower the patient to make decisions, including which medications to taper first and how fast. Successful tapers may take years.
- 4. Assess the patient for opioid use disorder and start discussing medication options right away.** Patients may find it challenging to accept an opioid use disorder diagnosis; give them time.
- 5. Document opioid stewardship and the rationale for the treatment plan.** Investigations into opioid prescribing are often based on insufficient documentation.

# TREATMENT OF WITHDRAWAL SYMPTOMS

<b>Consider Use of Adjuvant Medications During Taper</b> <sup>9-16</sup> Generally Not Needed if Utilizing a Gradual Taper	
Withdrawal symptoms (not effective for anxiety, restlessness, insomnia, and muscular aching)	<ul style="list-style-type: none"> <li>○ Clonidine 0.1 -0.2 mg oral every 6-8 hours; hold dose if blood pressure &lt;90/60 mmHg (0.1-0.2 mg 2-4 times daily is commonly used in the outpatient setting)</li> <li>○ Recommend test dose (0.1 mg oral) with blood pressure check one hour post dose ; obtain daily blood pressure checks; increasing dose requires additional blood pressure checks</li> <li>○ Reevaluate in 3-7 days; taper to stop; Average duration 15 days</li> <li>○ Baclofen 5mg 3 x daily may increase to 40 mg total daily dose<sup>6-9</sup> <ul style="list-style-type: none"> <li>○ Reevaluate in 3-7 days; average duration 15 days</li> <li>○ May continue after acute withdrawal to help decrease cravings</li> <li>○ Should be tapered when baclofen is discontinued</li> </ul> </li> <li>○ Gabapentin start at 100-300mg and titrate to 1800-2100mg divided in 2-3 daily doses           <ul style="list-style-type: none"> <li>○ Can help reduce withdrawal symptoms and help with pain and sleep</li> </ul> </li> </ul>
Anxiety, dysphoria, lacrimation, rhinorrhea	<ul style="list-style-type: none"> <li>○ Hydroxyzine 25-50 mg three times a day as needed</li> <li>○ Diphenhydramine 25 mg every 6 hours as needed</li> </ul>
Myalgias	<ul style="list-style-type: none"> <li>○ NSAIDs (e.g. naproxen 375-500 mg twice daily or ibuprofen 400-600 mg four times daily)</li> <li>○ Acetaminophen 650 mg every 6 hrs as needed</li> </ul>
Sleep disturbance	<ul style="list-style-type: none"> <li>○ Trazodone 25-300 mg orally at bedtime</li> </ul>
Nausea	<ul style="list-style-type: none"> <li>○ Prochlorperazine 5-10 mg every 4 hrs as needed</li> <li>○ Promethazine 25mg orally or rectally every 6 hours as needed</li> <li>○ Ondansetron 8mg every 12 hours as needed</li> </ul>
Diarrhea	<ul style="list-style-type: none"> <li>○ Loperamide 4 mg orally initially, then 2mg with each loose stool, not to exceed 16 mg daily</li> <li>○ Bismuth subsalicylate 524 mg every 0.5- 1 hour orally, not to exceed 4192 mg/day</li> </ul>

---

# NEED FOR OPIOIDS



“Opiophobia”

“No pain left behind”

**Responsible Opioid Pharmacotherapy**

---

# CONCLUSION

- Opioid epidemic requires a huge cultural shift where EVERYONE takes responsibility
- State and Federal regulatory bodies are identifying key metrics to identify adoption of opioid reduction strategies
- EDUCATION !! Set REALISTIC patient expectation
- Consider alternative therapies prior to prescribing opioid
- Be INTENTIONAL about opioid prescribing
  - Reassess, Reassess, Reassess
- Educate on diversion risks & how to safely store/dispose of opioids CDC Guidelines are guidelines not scripture
- Opioids stewardship can improve your community

# HIGH USE AREAS - PRODUCT AVAILABILITY

- Anesthesia narcotic packs

**2016**

Ketamine 50mg  
Hydromorphone 4mg  
Fentanyl (2) X 250mcg vials  
Fentanyl (2) X 100mcg vials  
Midazolam (2) X 5mg vials

**2017**

Ketamine 50mg  
Hydromorphone 2mg  
Fentanyl (2) X 100mcg vials  
Midazolam 5mg vial


**2018**

Ketamine 30mg  
Hydromorphone 1mg  
Fentanyl 100mcg vial  
Midazolam 2mg syringe

**2019**

Ketamine 30mg  
Hydromorphone 0.5mg syringe  
Fentanyl 100mcg vial  
Midazolam 2mg syringe

- Emergency Room standardization
  - Reinforce WHO recommendations on pain
  - Standardize to lowest dosage forms available





---

# LOCAL, STATE, AND FEDERAL OUTREACH

- E.C.H.O. Empowering Communities for Health Outcomes
- Speaking Opportunities
  - Prisma Health Grand Rounds
  - SC Birth Outcomes Initiative
  - SC Medical Association
  - American Dental Association
  - Governor's Opioid Summit
- Aligning with state political partners
  - Reports sent to Senator Graham and Governor McMaster outlining our ongoing opioid stewardship efforts
  - Research grants establishing best practices for SC through DAODAS
- National efforts:
  - Prisma Health Upstate efforts incorporated into the US Senate Congressional Testimony on Combating the US Opioid crisis

# MOVING THE NEEDLE IN SOUTH CAROLINA

## **JOINT ADVISORY OPINION ISSUED BY THE SOUTH CAROLINA STATE BOARDS OF MEDICAL EXAMINERS, NURSING AND PHARMACY REGARDING THE USE OF LOW DOSE KETAMINE INFUSIONS FOR THE MANAGEMENT OF PAIN THROUGHOUT THE GREENVILLE HEALTH SYSTEM<sup>1</sup>**

The State Boards of Medical Examiners, Nursing and Pharmacy hereby approve this request, but emphasize that the approval of low dose Ketamine infusions for the management of pain applies **only** to the Greenville Health System. Any other provider interested in developing a similar program should submit a request for review and input from the Healthcare Collaborative Committee.


Formulated: April 12, 2019

Revised: December 6, 2019; July 10, 2020<sup>1</sup>

The South Carolina State Board of Medical Examiners, the South Carolina State Board of Pharmacy, and the South Carolina State Board of Nursing acknowledge that:

It is within the scope of practice for an RN to administer/monitor low dose Ketamine via continuous infusion and intravenous push (in ED and PACU ONLY) with physician orders for specific cases of acute pain management in patients who with opioid-tolerance, intractable post-operative pain, poorly controlled chronic pain, palliative care, or patients suffering from extreme opioid side effects in an acute care setting.

## **Alternatives to Opioids (ALTO<sup>®</sup>) Acute Pain Protocols**



PRIVILEGED AND CONFIDENTIAL

protected pursuant to S.C. Code Ann. §§44-7-390 et seq. and 40-71-10 et seq.

# LOCAL, STATE, AND FEDERAL INVOLVEMENT



---

# FUTURE NEEDS?



---

NOW WE ARE HERE TO SHARE...



---

# Thank You

## Email Contacts:

- Kevin Walker, MD FASA [Kevin.Walker@PrismaHealth.org](mailto:Kevin.Walker@PrismaHealth.org)

